DEA role must be clearly defined in controlled substance Rx via telemedicine, expert cautions

If the DEA's role is not properly limited, there could be an overreach where the agency influences or even dictates how healthcare practitioners make decisions, which could impact patient care, says Dan Cohen, president of RTM company Adhere+.

Read alsoLab critical to medical device development 'DOGEd'

Read alsoA Chartis AI expert lays out a detailed vision for AI in healthcare

Read alsoSingapore unveils online health insurance planning tool and more briefs

Read alsoLatest telehealth service expansions in Australia and more briefs

from News from healthcareitnews.com https://ift.tt/WOtK6BT

Fitxplore

Main menu

Pages

DEA role must be clearly defined in controlled substance Rx via telemedicine, expert cautions

Latest articles from : News from healthcareitnews.com

For hospital IT purchasers, resource strain and optimal ROI are top concerns

AI being used more often at point of care, KLAS research shows

Te Whatu Ora reveals IT breach in Central region

Australia taps Medibank's Amplar Health for virtual aged care nursing trial

HIMSSCast: The advocacy plans of the newly combined ATA Action and DTA

Lawmakers target DOGE threats to veterans' healthcare, data privacy

Comments

Post a Comment